Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia, according to two studies published in Blood Advances.

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their highly effective vaccines to fight the virus.

Researchers at the University of Chicago have developed a “universal” chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing barriers in cancer immunotherapy. Promising initial testing results, published in Science Advances, suggest that this new form of CAR-T cell therapy could dramatically change the treatment landscape for certain cancers.

Australian researchers have used an innovative genome-wide screening approach to identify genes, and their encoded proteins, that play critical roles in the prevention of lymphoma development, revealing new potential treatment targets for these blood cancers.

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.

As we age, our cells replicate, and the DNA in these cells can acquire mistakes—or mutations—every time the sequence is copied. Most newly acquired mutations are harmless, but some can tip the balance toward cancer development later in life.

A new Northwestern Medicine study has revealed how a common inherited mutation disrupts red blood cell development and sparks inflammation that can lead to leukemia, according to findings published in Nature Communications.